Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina-Reference-Cited by-同舟云学术

Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina

Published:2022-04-14 Issue:3 Volume:45 Page:45-51
ISSN:1537-162X
Container-title:Clinical Neuropharmacology
language:en
Short-container-title:Clin Neuropharm

Author:

Rojas Juan Ignacio,Patrucco Liliana,Alonso Ricardo,Garcea Orlando,Deri Norma,Carnero Contentti Edgar,Lopez Pablo A.,Pettinicchi Juan Pablo,Caride Alejandro,Cristiano Edgardo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Neurology (clinical),Pharmacology

Reference25 articles.

1. Multiple sclerosis;N Engl J Med,2018

2. Evolving concepts in the treatment of relapsing multiple sclerosis;Lancet,2017

3. Induction vs. escalating therapy in multiple sclerosis: practical implications;Neurol Sci,2008

4. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response;Brain,2017

5. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study;Lancet Neurol,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Burden of treatment and quality of life in relapsing remitting multiple sclerosis patients under early high efficacy therapy in Argentina: Data from the Argentinean registry;Multiple Sclerosis and Related Disorders;2024-05

2. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study;Clinical Neurology and Neurosurgery;2024-05

3. Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France;Neurology and Therapy;2024-03-15

4. Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria;Journal of Neurology;2024-03-02

5. Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina;Multiple Sclerosis and Related Disorders;2023-11